News Commentary | April 16, 2021
Omada Health has rolled out a product offering that leverages last year's acquisition of Physera. The offering accomplishes two things. First, it helps further flesh out the ecosystem that Omada has built beyond just diabetes care, creating a "one‑stop shop" for customers needing multiple modes of ... Not part of subscription
News Commentary | June 23, 2021
The funding accelerates growth in the EU and enables expansion to the U.S. The solution includes an app and a wearable blood glucose tracker that has a tiny rubbery subcutaneous part and can accurately function for 14 days. The solution continuously measures blood sugar levels and provides real‑time... Not part of subscription
News Commentary | December 22, 2021
Remote blood‑diagnostic‑device maker Tasso received a $100 million Series B cash infusion in response to a surge in demand for at‑home blood testing in the pandemic era. The investment round was led by RA Capital Management, and Tasso plans to use the funds primarily to scale the production of its ... Not part of subscription
by Danielle Bradnan
This research study to identify digital biomarkers comes on the heels of other studies based on smartphones and other wearables for early detection of other medical conditions, such as dementia and depression – as well as, in a notable study with Fitbit, the flu. This research is not only important for developing new tools to get a preliminary diagnosis in advance of testing for COVID-19 but also for advancing research for disease and population health management in the years to come after this crisis has passed. Clients should be looking for research partnerships with wearables startups to identify these biomarkers now as a way to not only mitigate the current crisis but also continue future plays in healthcare.
For the original news article, click here .